Remove Antibody Remove Drug Delivery Systems Remove Production
article thumbnail

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Pharmaceutical Technology

Due to their size, cells can absorb them where they release products. Libera Bio is using these nanocarriers , developed by the company’s cofounder MJ Alonso, PhD, professor, Department for Pharmacy and Pharmaceutical Technology, Universidade de Santiago de Compostela, to deliver antibodies.

article thumbnail

Conjugation and Labeling of Molecules: A Burgeoning Approach in Therapeutics Development and Molecular Imaging

Roots Analysis

Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030

Roots Analysis

Advances in drug discovery and development technologies / platforms have increased the likelihood of targeting a number of the aforementioned types of biological targets. As a result, novel product development opportunities have emerged and are likely to benefit both drug developers and investors alike.

article thumbnail

Liposomes Development: Service Providers Landscape

Roots Analysis

This can be attributed to the fact that liposomes can actively target tumor tissues when used in combination with antibodies. These platforms have created an opportunity for the product developers to share their innovative ideas in this domain.

article thumbnail

Next Generation Complement Therapeutics: Potential Life-Changing Therapies for Multiple Rare Disorders

Roots Analysis

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics Market.

article thumbnail

Autoinjector: Empowering The Healthcare Industry

Roots Analysis

In the dynamic landscape of the healthcare sector, the evolution of drug delivery systems plays a significant role in transforming the management of chronic diseases. Reduce Risk of Contamination: Since the product is sealed at the production facility, the chances of microbial contamination are reduced significantly.

article thumbnail

Top Emerging Therapies To Watch Out for in the Retinal Vein Occlusion Market

Delveinsight

Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Brolucizumab is a humanized single-chain antibody fragment (scFv). The company has plans to initiate new trials for the product however not until the second half of 2021.